Olav Fromm – Managing Director, Chiesi Nordics
Olav Fromm, managing director of Chiesi Nordics, explains the deep roots of Chiesi in Sweden, where its blockbuster drug, a surfactant for treating neonatal babies, was developed. He also touches…
Chiesi is an international, privately-owned pharmaceutical company with its Corporate Head Office based in Parma, Italy. Chiesi is dedicated to the research, development and sales of innovative, therapeutic prescription medicines in the fields of respiratory, neonatology, transplant medicine and rare diseases. Founded in 1935, as a family firm, today, Chiesi spans the globe, employing more than 5000 people in 26 affiliates worldwide and distributes its products in more than 70 countries.
In the Nordics, Chiesi Pharma AB employs more than 50 dedicated employees, who are based out of our head office in Central Stockholm, the recently integrated Research and Development Centre at Lidingö outside Stockholm or are part of our experienced field-based sales teams. As with every part of the Chiesi group, we embrace a shared set of values and a common code of ethical conduct. This demands the highest standards of reliability, transparency, and individual accountability in everything we do. It emphasizes the importance of collaborative working, putting people first and exchanging knowledge. Implicit in all of these values is a responsible attitude to the social and environmental impact of our actions.
Contact
Klara Norra kyrkogata 34, 111 22 Stockholm
Tel: 08-753 35 20
Olav Fromm, managing director of Chiesi Nordics, explains the deep roots of Chiesi in Sweden, where its blockbuster drug, a surfactant for treating neonatal babies, was developed. He also touches…
PharmaBoardroom caught up with Niklas Hedberg at DIA Europe 2024 in Brussels to gauge what more needs to be done ahead of the implementation of European HTA regulation in January…
The recent FDA decision to investigate the serious risk of patients developing new cancers after treatment with CAR-T therapies may have created some bad press around cell and gene therapies,…
Svante Paabo has won the 2022 Nobel Prize in physiology or medicine for his ground-breaking work in paleogenetics. Paabo’s research – which includes sequencing the genome of the Neanderthal for…
Anders Blanck, CEO of LIF, the industry organisation for the research-based pharmaceutical industry in Sweden, describes the Sustainability Strategy that the pharma industry in Sweden is now launching. Central to…
Denmark boasts plenty of strong fundamentals as a clinical trials hub, but is perhaps constrained by a population of just 5.8 million and a correspondingly small patient pool. However, international…
In the wake of the 2021 United Nations Climate Change Conference (COP26), sustainability is once more a hot-button issue across all industries, including pharma. Here, Marco Rauland, vice president global…
Petter Hartman of the Medicon Valley Alliance, a non-profit membership organisation spanning the Danish-Swedish life science cluster Medicon Valley, introduces the progress of the Alliance from a networking body to…
In a wide-ranging interview, AbbVie’s Linn Mandahl discusses how the reorganisation of Scandinavian operations back in 2018 has put the company back on a growth trajectory in the region. Mandahl…
Anders Blanck, CEO of Lif, the trade association for the research-based Swedish pharmaceutical industry, writes about the challenges the world faces from antimicrobial resistance (AMR). Sweden has for decades been…
Anders Blanck of Lif, the trade association for the research-based Swedish pharmaceutical industry, outlines the steps already being put in place for Sweden to become a leading country in the…
Niklas Hedberg outlines the role of EUnetHTA as both a network and project built up of national HTAs in Europe, the potential for a continent-wide mandate on health technology assessment,…
Sweden’s USD 4.8 billion pharmaceutical market, its population size of 10 million and marginal positioning on the northerly fringe of the European Union all belie a legacy as a real…
See our Cookie Privacy Policy Here
